0001193125-26-130489
SEC filingQuince Therapeutics settled approximately $16.4 million of EIB debt obligations for a $5.5 million payment, fully discharging the company's liabilities under the Finance Documents.
Quince Therapeutics announced the full settlement of its outstanding debt obligations to the European Investment Bank (EIB), marking a significant financial restructuring milestone. The company paid EUR 4,800,000, approximately $5.5 million, to satisfy total outstanding obligations of approximately $16.4 million as of March 27, 2026. This settlement represents a substantial debt reduction, effectively discharging the liabilities of both Quince Therapeutics, Inc. and its subsidiary, Quince Therapeutics S.p.A., under the Finance Contract and related Guarantee Agreement originally entered into in July 2020. Management characterized this action as removing a substantial overhang that had constrained the company's flexibility. With the debt resolved, Quince Therapeutics intends to advance its corporate restructuring and the evaluation of strategic alternatives aimed at maximizing shareholder value. The alternatives under consideration include merger, reverse merger, asset sale, or other strategic transactions.